Dexamethasone

Dexamethasone

SCHEMBL337333

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO.O=P([O-])([O-])O.[Na+].[Na+]

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

NR3C1

The experimentally established mechanism targets of Dexamethasone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 known ✓ P04150 7/20 0.89
HIF1A Q16665 9/20 0.89
CYP3A4 P08684 7/20 0.89
HSD17B10 Q99714 4/20 0.89
NFKB1 P19838 3/20 0.89
PGR P06401 3/20 0.89
TSHR P16473 2/20 0.89
AR P10275 2/20 0.89
PMP22 Q01453 2/20 0.89
MEN1 O00255 1/20 0.89
CYP2D6 P10635 1/20 0.89
KMT2A Q03164 1/20 0.89
APEX1 P27695 1/20 0.89
NPSR1 Q6W5P4 1/20 0.89
IKBKB O14920 1/20 0.89
CHUK O15111 1/20 0.89
ADRB2 P07550 1/20 0.89
NR3C2 P08235 1/20 0.89
PLA2G2A P14555 1/20 0.89
NFKB2 Q00653 1/20 0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Betamethasone SCHEMBL27582183 1.00 HIF1A (0.89) HIF1ACYP3A4NR3C1HSD17B10NFKB1
Betamethasone SCHEMBL15415155 0.98 HIF1A (0.89) HIF1ACYP3A4NR3C1HSD17B10NFKB1
Dexamethasone SCHEMBL3836634 0.98 HIF1A (0.89) HIF1ACYP3A4NR3C1HSD17B10NFKB1
Betamethasone SCHEMBL1301201 0.97 HIF1A (0.90) HIF1ACYP3A4NR3C1HSD17B10NFKB1
Betamethasone SCHEMBL7779 0.97 HIF1A (0.90) HIF1ACYP3A4NR3C1HSD17B10NFKB1
Betamethasone SCHEMBL6908689 0.97 HIF1A (0.90) HIF1ACYP3A4NR3C1HSD17B10NFKB1
Betamethasone SCHEMBL8508844 0.97 HIF1A (0.90) HIF1ACYP3A4NR3C1HSD17B10NFKB1
Betamethasone SCHEMBL13740162 0.97 HIF1A (0.86) HIF1ACYP3A4NR3C1HSD17B10NFKB1
Betamethasone SCHEMBL12099597 0.97 HIF1A (0.89) HIF1ACYP3A4NR3C1HSD17B10NFKB1
Betamethasone SCHEMBL5501682 0.96 HIF1A (0.93) HIF1ACYP3A4NR3C1HSD17B10NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3946265-B1 OTOLOGIC COMPOSITIONS NTC S R L (IT) 2024-12-04 EP claimed
CN-114381768-B Preparation method for constructing photodynamic antibacterial bone dexamethasone/hydroxyapatite coating by polypyrrole regulated copper nano particles 新疆师范大学 2024-02-06 CN claimed
CN-114381768-A Preparation method of photodynamic antibacterial osteogenesis-promoting dexamethasone/hydroxyapatite coating constructed by polypyrrole-regulated copper nanoparticles 新疆师范大学 2022-04-22 CN claimed
CN-113677327-A Otological compositions NTC有限公司 2021-11-19 CN claimed
CN-107532201-B Method for assessing response of patients with ataxia telangiectasia to glucocorticoid therapy 爱瑞德勒股份有限公司 2021-05-11 CN claimed
US-9028860-B2 Partially microcellular, selectively hydrophilic composite construct for ocular drug delivery POLY-MED, INC. (US) 2015-05-12 US claimed
WO-2014061937-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION COMPRISING PIPERACILLIN OR ITS SALT, TAZOBACTAM OR ITS SALT AND DEXAMETHASONE PHOSPHATE OR ITS SALT YUHAN CORPORATION (KR) 2014-04-24 WO claimed
WO-2014010924-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION COMPRISING VANCOMYCIN OR ITS SALT AND DEXAMETHASONE PHOSPHATE OR ITS SALT YUHAN CORPORATION (KR) 2014-01-16 WO claimed
US-20110268783-A1 PARTIALLY MICROCELLULAR, SELECTIVELY HYDROPHILIC COMPOSITE CONSTRUCT FOR OCULAR DRUG DELIVERY POLY-MED, INC. (US) 2011-11-03 US claimed
EP-1913948-B1 Re-epithelializing pharmaceutical compositions containing xanthan gum SIFI SPA (IT) 2011-10-12 EP claimed
WO-2011031018-A2 WATER-SOLUBLE DRUG DELIVERY SYSTEM ALLOWING SLOW RELEASE 한남대학교 산학협력단 (KR) 2011-03-17 WO claimed
US-20080146530-A1 Dexamethasone disodium phosphate; netilmicin sulfate; xanthan gum; sodium (di)hydrogen phosphate buffer; sodium citrate; and water; ophthalmology; vision defects; corneal epithelial cells; wound healing agents SIFI S.P.A. (IT) 2008-06-19 US claimed
EP-1913948-A1 Re-epithelializing pharmaceutical compositions containing xanthan gum Sifi S.p.A (IT) 2008-04-23 EP claimed
US-20080038316-A1 Conveniently implantable sustained release drug compositions RAMSCOR, INC. 2008-02-14 US claimed
US-20050234011-A1 Use of composition of xanthan gum mixed with hyaluronic acid speeds up and improves advantageously the formation of newly grown epithelium, especially of corneal tissue SIFI S.P.A. (IT) 2005-10-20 US claimed
EP-1358883-A1 Re-epithelializing pharmaceutical compositions containing xanthan gum Sifi S.p.A (IT) 2003-11-05 EP claimed
US-5147291-A Sound transmission apparatus for uniformly administering chemical composition through the skin CUKIER A DAVID (US) 1992-09-15 US claimed
EP-4373495-B1 BUDESONIDE 21-PHOSPHATE SODIUM SALT FOR USE AS ANTI-INFLAMMATORY OR ANTI-ASTHMATIC AGENT GENETIC S P A (IT) 2025-11-19 EP disclosed
US-4432964-A Topical composition containing steroid in two forms released independently from polymeric carrier ALZA CORPORATION (US) 1984-02-21 US disclosed
US-4304765-A Ocular insert housing steroid in two different therapeutic forms ALZA CORPORATION (US) 1981-12-08 US disclosed